Marina Biotech concludes CEQ508 9 month toxicology study
CEQ508 is currently in a Phase 1b/2a clinical development program and is intended for the treatment of Familial Adenomatous Polyposis. CEQ508 comprises attenuated bacteria that are engineered to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.